跳至主要内容
临床试验/NCT03033927
NCT03033927
进行中(未招募)
不适用

Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response

Memorial Sloan Kettering Cancer Center8 个研究点 分布在 1 个国家目标入组 74 人2017年1月24日

概览

阶段
不适用
干预措施
CTC isolocation and analysis
疾病 / 适应症
Pancreatic Cancer
发起方
Memorial Sloan Kettering Cancer Center
入组人数
74
试验地点
8
主要终点
Progression Free Survival
状态
进行中(未招募)
最后更新
5天前

概览

简要总结

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

注册库
clinicaltrials.gov
开始日期
2017年1月24日
结束日期
2027年1月24日
最后更新
5天前
研究类型
Observational
性别
All

研究者

入排标准

入选标准

  • Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
  • Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
  • Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
  • ECOG performance status 0-
  • A minimum age of 18 years old.

排除标准

  • Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
  • Known to be HIV positive on antiretroviral therapy
  • Prior organ allograft
  • Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

研究组 & 干预措施

Participants with Stage IV Pancreatic Cancer

干预措施: CTC isolocation and analysis

结局指标

主要结局

Progression Free Survival

时间窗: 36 months

in patients receiving frontline therapy predicted to be effective versus ineffective based on CTC PGx analysis

研究点 (8)

Loading locations...

相似试验